A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50  mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis

Etanercept, a soluble tumor necrosis factor receptor, and acitretin have been shown to be effective in treating psoriasis. Acitretin is widely used in Korea. However, the combination of etanercept plus acitret...
Source: BMC Dermatology - Category: Dermatology Authors: Source Type: research